Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

99
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
99
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

107
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
107
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

69
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
69
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

645
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

80
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
80
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

117
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
117

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

JAMA cardiology·2026
Same author

Comprehensive Clinical Benefit of CCM in HFrEF Patients - a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

Universal Pulmonary Resistance-Compliance Relationship: And Why It Matters?

Circulation. Heart failure·2026
Same author

De Novo Aortic Insufficiency and Its Progression in Patients on Microaxial Flow Pump Support Before Durable Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

SBK2 Links Cardiac Stress Signaling to Mitochondrial Proteostasis.

Circulation research·2026
Same journal

Myeloid Piezo1 as a Brake on Efferocytosis and Cardiac Repair in the Infarcted Heart.

Circulation research·2026
Same journal

Targeting Late Na<sup>+</sup> Current: Too Late or Better Late Than Never?

Circulation research·2026
Same journal

HFpEF-Any: Human Single-Nuclear Transcriptomics Challenging the Translational Validity of Current HFpEF Models.

Circulation research·2026
Same journal

Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.

Circulation research·2026
Same journal

Meet the First Authors.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Nov 5, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K

Reverse Remodeling With Left Ventricular Assist Devices.

Daniel Burkhoff1, Veli K Topkara1, Gabriel Sayer1

  • 1Cardiovascular Research Foundation, New York, NY (D.B.).

Circulation Research
|May 13, 2021
PubMed
Summary
This summary is machine-generated.

Left ventricular assist devices (LVADs) have advanced heart failure treatment over 25 years. Research shows LVADs improve outcomes and offer insights into heart failure biology and myocardial recovery.

Keywords:
biologyheart failuremyocardiumtechnologytherapeutics

More Related Videos

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.6K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.1K

Related Experiment Videos

Last Updated: Nov 5, 2025

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

5.3K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.6K
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

3.1K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Heart Failure Research

Background:

  • Severe end-stage heart failure significantly impacts patient outcomes and quality of life.
  • Left ventricular assist devices (LVADs) represent a critical therapeutic option for advanced heart failure.
  • Understanding the biological effects of LVADs is crucial for improving patient management.

Purpose of the Study:

  • To review the development and clinical outcomes of LVADs over the past 25+ years.
  • To explore the biological insights gained from studying hearts and myocardium in patients with LVAD support.
  • To discuss the mechanisms of reverse remodeling and factors influencing myocardial recovery.

Main Methods:

  • Comprehensive literature review of research on LVAD development and clinical outcomes.
  • Analysis of hemodynamic effects and ventricular unloading associated with LVADs.
  • Examination of structural, cellular, and molecular changes in the myocardium during LVAD support.

Main Results:

  • LVAD technology has evolved, improving clinical outcomes in severe heart failure.
  • LVAD support leads to ventricular unloading and promotes reverse remodeling.
  • Synergistic effects of LVADs and medical therapies can lead to heart failure remission and myocardial recovery.

Conclusions:

  • LVADs are a vital therapy for end-stage heart failure, offering significant clinical benefits.
  • Studies of LVAD-supported hearts provide fundamental insights into heart failure biology.
  • Further research is needed to overcome impediments to myocardial recovery in most LVAD patients.